Stocks of Flu Vaccine Developers Rise as Flu Activity Increases

Investing.com -- Stocks of vaccine developers, including Moderna and CureVac, surged in pre-market trading on Monday as seasonal flu activity intensified across the United States. Moderna's stock increased by as much as 3.4%, while CureVac's shares rose by up to 13%.

Other vaccine manufacturers also saw their stock prices rise. Novavax's shares were up by 3.1%, while BioNTech (NASDAQ:BNTX) recorded a 1.4% increase.

The latest weekly report from the Arkansas Department of Health indicated a significant rise in flu activity in the state. The report, ending on December 28, 2024, showed that flu activity reached a "Very High" level of 11 on a 13-point scale. This represents a notable increase compared to the previous two weeks, which were classified as "High." At the beginning of the month, flu activity was reported as "Low."

This marks the first time since the flu season began on September 30 that a "Very High" ranking has been reported. The increase in flu activity is likely contributing to heightened interest in vaccine developer stocks.